Lung cancer is divided into 2 main categories that require different therapies. Most of the new therapies are for the common type, but recently, immunotherapy has shown promise for this less common lung cancer type.
Although most of the drugs being developed for lung cancer these days are for non–small-cell lung cancer (NSCLC), there may be a shift on the horizon as new treatment options emerge for patients with small-cell lung cancer.
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer.
Not sure what immunotherapy is and how it works? Read about the cellular mechanism and the various types of immunotherapies, including those that use your own immune system to destroy cancer cells. This article also addresses the side effects of immunotherapy.
Breast cancer is the second
most common cancer
among women, but it
is important to remember
that men can also have breast
cancer. Recent advances in
therapy have led to the discovery
of specific biologic markers
(biomarkers) in cancer cells,
which has further led to the development
of drugs known as
Brukinsa, which was approved for use in patients with mantle-cell leukemia in late 2019, has also showed promising results in 2 recent clinical trials of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities.
Among Americans diagnosed with multiple myeloma, black and Hispanic patients receive their first treatment about 3 months later than white patients. Delays in treatment means unnecessary complications. Closing this racial gap is therefore paramount.
A new study makes clear that limited access to health insurance or insufficient insurance coverage accounts for much of the disparity in outcomes seen between black and white patients with cancer in the United States.
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Recently, several new drug combinations without chemotherapy have been approved by the FDA for patients with CLL, providing patients new options when their cancer stops responding to current treatment.
Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
Triple-negative breast cancer has few treatment options. Promising results from recent clinical trials of immunotherapy combined with chemotherapy in patients with metastatic disease may soon change the way this aggressive cancer is treated. Just after this article was written, the FDA approved this combination for patients with triple-negative breast cancer.
After many years in development, the newest type of immunotherapy known as CAR T-cell therapy (or gene therapy) is becoming a mainstream treatment in some types of blood cancer, specifically in leukemia and lymphoma.
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Patients who are receiving immunotherapy should consult with their doctor immediately if and when any side effects occur, because immune-related adverse events may occur during therapy or even after discontinuation of therapy.
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer.
Depression among cancer survivors is associated with an increased risk for suicide, poor quality of life, increased mortality risk, delayed return to work, and more frequent use of healthcare resources, which increases their medical costs.
Paying for cancer treatment can be challenging even for patients who have insurance. This article lists the national organizations and foundations that provide direct financial assistance for patients with cancer who are having difficulties paying for their cancer care.
The year 2015 will go down in medical history as an exceptional moment in the progress made in multiple myeloma, with 4 new drugs having been approved by the FDA and 1 drug already in use for patients with advanced disease being approved for use in all patients, including those who were just diagnosed with the disease. Although no cure is available yet, these new drugs bring significant progress to the treatment of patients with multiple myeloma.
Chronic myeloid leukemia (CML) is a blood cancer that results from a genetic abnormality that causes the production of too many white blood cells in the bone marrow. However, CML is not a genetic disease that runs in families.
Last modified: January 13, 2020
Subscribe to CONQUER™: the patient voice™
Receive timely cancer news & updates, patient stories, and more.